Stocks and Investing Stocks and Investing
Wed, March 15, 2023
Tue, March 14, 2023

Scott Fidel Reiterated (AMED) at Hold and Held Target at $103 on, Mar 14th, 2023


Published on 2024-10-28 02:16:13 - WOPRAI, Scott Fidel
  Print publication without navigation


Scott Fidel of Stephens & Co., Reiterated "Amedisys, Inc." (AMED) at Hold and Held Target at $103 on, Mar 14th, 2023.

Scott has made no other calls on AMED in the last 4 months.



There are 6 other peers that have a rating on AMED. Out of the 6 peers that are also analyzing AMED, 2 agree with Scott's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Steve Valiquette of "Barclays" Initiated at Hold and Held Target at $93 on, Monday, March 13th, 2023
  • Whit Mayo of "SVB Leerink" Maintained at Hold with Decreased Target to $85 on, Thursday, January 5th, 2023


These are the ratings of the 4 analyists that currently disagree with Scott


  • Jonathan Yong of "Credit Suisse" Reiterated at Buy and Held Target at $115 on, Monday, February 27th, 2023
  • Ben Hendrix of "RBC Capital" Maintained at Buy with Decreased Target to $111 on, Tuesday, February 21st, 2023
  • Mark Miller of "Benchmark" Maintained at Strong Buy with Decreased Target to $115 on, Thursday, February 16th, 2023
  • Colin Rusch of "Oppenheimer" Maintained at Buy with Decreased Target to $125 on, Thursday, January 19th, 2023

Contributing Sources